RNA-LNP vaccines have played a pivotal role in the global response to the COVID-19 pandemic and are advancing against a wide range of other infectious diseases.

Navigating the complexity and diversity of RNA-LNP approaches present challenges for the research and manufacturing phases. However, to overcome these challenges, we are strategizing for the swift advancement of promising RNA-LNP drug candidates for clinical evaluation and successful commercialization.

In this webinar, we offer a detailed exploration of how these strategies empower research scientists to discover and develop new RNA-LNP-based vaccines efficiently. This includes spotlighting a successful collaboration with Replicate Bioscience in developing a self-replicating RNA (srRNA) vaccine targeting infectious diseases.

Their interim phase 1 clinical data demonstrates exceptional immune protection achieved at the lowest dose tested (0.1 mcg) with a clean safety profile up to the highest dose tested (10 mcg). The immunogenicity and safety improvement represents a new standard for the RNA field expanding its potential application across complex infectious diseases, oncology, and protein replacement therapy.

Learning Objectives:

• End-to-end RNA-LNP workflows from research to GMP manufacturing, with strategies to overcome scale-up and process development challenges in vaccine development
• Strategies for mapping clinical development milestones, including data and document packages to enable regulatory submissions
• Next-generation srRNA shows significant clinical bioactivity improvements, demonstrating the ability to confer protection at very low doses without a corresponding increase in toxicity

Lloyd Jeffs, Ph.D.

Strategic Customer Leader, Cytiva

Andrew Geall, Ph.D.

Chief Scientific Officer, Replicate Bioscience,